Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study
12:21pm, Thursday, 23'rd Jan 2025
Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
03:43pm, Wednesday, 22'nd Jan 2025
Stifel initiated coverage on Cytokinetics Incorporated CYTK, noting the company's catalyst rich one to two years.
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
07:30am, Monday, 13'th Jan 2025
PDUFA Target Action Date for Aficamten Set for September 26, 2025; Commercial Launch Preparations Underway for First Potential Approval
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
04:00pm, Monday, 06'th Jan 2025
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to pre
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:00pm, Friday, 03'rd Jan 2025
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2024 it granted stock options to purchase an aggregate of
Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution
08:30am, Tuesday, 31'st Dec 2024
Cytokinetics is advancing aficamten, a potential competitor to Camzyos, targeting hypertrophic cardiomyopathy (HCM). Strategic licensing deals with Sanofi and Bayer secure resources and focus US comme
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorizat
Why Cytokinetics Stock Was a Nearly 5% Winner Today
05:25pm, Friday, 20'th Dec 2024
California-based biotech Cytokinetcs (CYTK 4.56%) finished the trading week in style, as its stock price outperformed many other titles by rising nearly 5% on Friday. News of a fresh licensing deal in
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
12:00am, Friday, 20'th Dec 2024
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamt
Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?
06:49am, Monday, 09'th Dec 2024
Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug
01:30pm, Wednesday, 04'th Dec 2024
CYTK opens enrollment in the phase III COMET-HF study on omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Tuesday, 03'rd Dec 2024
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 29, 2024 it granted stock options to purchase an aggregate of
FDA Accepts Cytokinetics' Application for Cardiovascular Drug
02:40pm, Tuesday, 03'rd Dec 2024
CYTK's NDA is seeking approval for the lead pipeline candidate, aficamten, which the FDA accepted and assigned a target action date of Sept. 26, 2025.
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that COMET-HF (Confirmation of O mecamtiv M ecarbil Efficacy Trial in Heart Fai
